PRESS RELEASE published on 06/25/2025 at 18:00, 1 year 2 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC over verkoop van aandelen en onder drempel van 15% gegaan. Bedrijf richt zich op therapeutische innovatie met technologieën voor klinisch onderzoek Transparantiekennisgeving Aandelen Oxurion NV Atlas Special Opportunities II LLC Therapeutische Innovatie
PRESS RELEASE published on 06/25/2025 at 18:00, 1 year 2 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC indicating a decrease in shareholding below the threshold. The biopharmaceutical company is focused on therapeutic innovation and clinical research technologies Technology Clinical Research Transparency Notification Biopharmaceutical Oxurion NV
BRIEF published on 06/19/2025 at 08:35, 1 year 3 months ago Oxurion to Acquire Preclinical Microbiology CRO in Toulouse Acquisition Diversification Toulouse Oxurion Microbiology CRO
BRIEF published on 06/19/2025 at 08:35, 1 year 3 months ago Oxurion acquiert une CRO en microbiologie préclinique à Toulouse Acquisition Diversification Toulouse Oxurion CRO En Microbiologie
PRESS RELEASE published on 06/19/2025 at 08:30, 1 year 3 months ago Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een preklinische microbiologie-CRO om zich te diversifiëren en zijn aanwezigheid in de regio Toulouse te versterken Oxurion NV, een biofarmaceutisch bedrijf in Leuven, kondigt intentieovereenkomst voor de overname van onderneming gespecialiseerd in microbiologische diensten aan, ter versterking van expertise en strategie Stratégie Overname Oxurion NV Biofarmaceutisch Microbiologische Diensten
PRESS RELEASE published on 06/19/2025 at 08:30, 1 year 3 months ago Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region Oxurion NV announces LOI to acquire 70% share capital of preclinical microbiology services company. Economic details of the transaction and growth projections disclosed Acquisition Transaction Details Growth Projections Oxurion NV Preclinical Microbiology
PRESS RELEASE published on 06/19/2025 at 08:30, 1 year 3 months ago Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO de services précliniques en microbiologie afin de se diversifier et de renforcer sa présence en région toulousaine Oxurion NV signe une lettre d'intention pour l'acquisition de 70% d'une société spécialisée en microbiologie appliquée à la santé humaine et animale, dermocosmétiques et nutraceutiques Acquisition Biopharmaceutique Lettre D'intention Oxurion NV Microbiologie Appliquée
BRIEF published on 06/18/2025 at 18:05, 1 year 3 months ago Oxurion Announces Transparency Notification from Atlas Special Opportunities II LLC Transparency Notification Biopharmaceutical Atlas Special Opportunities Ownership Structure Oxurion
BRIEF published on 06/18/2025 at 18:05, 1 year 3 months ago Oxurion annonce une notification de transparence de la part d'Atlas Special Opportunities II LLC Biopharmaceutique Notification De Transparence Oxurion Opportunités Spéciales Atlas Structure De Propriété
PRESS RELEASE published on 06/18/2025 at 18:00, 1 year 3 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV announces receipt of transparency notification from Atlas Special Opportunities II, LLC regarding shareholding. Company combines therapeutic innovation with technology for clinical research Clinical Research Transparency Notification Biopharmaceutical Belgium Oxurion NV
Published on 09/22/2026 at 17:00, 1 hour 57 minutes ago Leggett Dynamics Expands Asia Pacific Headquarters
Published on 09/22/2026 at 16:30, 2 hours 27 minutes ago Formation Metals Intersects 0.98 g/t Au over 95.6 Metres Starting 7 Metres Below Surface, Including 3.14 g/t Au over the First 10 Metres, Extending the A-Zone Up to 50 Metres North at N2
Published on 09/22/2026 at 15:25, 3 hours 32 minutes ago Aztec Minerals Announces Closing of Upsized C$6.4 Million Bought Deal Private Placement Including Concurrent Exercise of Underwriter's Option
Published on 09/22/2026 at 15:20, 3 hours 37 minutes ago MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture
Published on 09/22/2026 at 18:45, 11 minutes ago MGI Digital Technology: Modification des ressources allouées au contrat de liquidité.
Published on 09/22/2026 at 18:30, 27 minutes ago Avolta partners with Hawaii’s Department of Transportation to expand airport dining at three airports
Published on 09/22/2026 at 18:30, 27 minutes ago Voyageurs du Monde: Communiqué sur le dépôt de projet de note en réponse (suite au dépôt de projet de note en réponse de Voyageurs du Monde à l'Autorité des Marchés Financiers)
Published on 09/22/2026 at 18:30, 27 minutes ago IEVA GROUP: Visioconférence actionnaires et investisseurs Jeudi 15 octobre 2026 - 18h00 (CEST)
Published on 09/22/2026 at 17:45, 1 hour 12 minutes ago Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Published on 09/22/2026 at 18:00, 57 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 57 minutes ago Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 1 hour 12 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
Published on 09/22/2026 at 17:45, 1 hour 12 minutes ago Imerys-09-2026-communique-capital-droits-de-vote-au-31-août-2026